Summary:
- Paradigm Therapeutics receives an additional $12.6M investment from Eshelman Ventures, bringing the total investment in 2025 to $25.1M.
- The funding will be used to accelerate activities related to the commercial launch of the SD-101 program, focusing on manufacturing and regulatory efforts.
- Paradigm Therapeutics is a clinical-stage pharmaceutical company dedicated to developing innovative therapies for rare diseases, with a focus on Epidermolysis Bullosa and their SD-101 treatment.
Article:
Paradigm Therapeutics Secures $12.6M Investment for SD-101 ProgramParadigm Therapeutics, a biopharmaceutical company based in Mount Pleasant, SC, has recently received an additional investment of $12.6M from Eshelman Ventures. This latest funding round brings the total investment for 2025 to an impressive $25.1M, highlighting the confidence investors have in the company’s mission and potential.
The primary goal of this new funding is to accelerate various activities associated with the anticipated commercial launch of the SD-101 program on a global scale. This includes crucial steps such as manufacturing and regulatory efforts, ensuring that the innovative therapy reaches patients in need as efficiently as possible.
Led by CEO Robert Ryan, Paradigm Therapeutics is a clinical-stage pharmaceutical company that is committed to addressing critical medical needs, particularly in the treatment of rare diseases such as Epidermolysis Bullosa (EB). Their SD-101 program, a topical cream designed to treat the skin effects in EB patients, has shown promising results in both Phase II and Phase III clinical trials. What sets SD-101 apart is its ease of use, as it requires no special handling and can be stored at room temperature, making it a convenient option for patients.
Overall, Paradigm Therapeutics is dedicated to making a meaningful impact in the field of rare disease treatment, with a specific focus on improving the lives of those affected by EB. The recent investment from Eshelman Ventures will undoubtedly help the company advance their mission and bring their innovative therapies to those who need them most.
By: [Your Name]
